TIDMOCTP
RNS Number : 6819M
Oxford Cannabinoid Tech.Holdings
16 January 2023
Oxford Cannabinoid Technologies Holdings plc
("OCTP" or the "Company")
Appointment of General Counsel & Company Secretary
Notice of Results
& Analyst and Investor Presentations
Oxford Cannabinoid Technologies Holdings plc, the pharmaceutical
company developing prescription cannabinoid medicines for approval
by global regulatory agencies and targeting the US$ multi-billion
pain market, is pleased to announce the appointment of Robin
("Rob") Bennett as General Counsel and Company Secretary. Rob
joined the Company in December 2022 as General Counsel and was
appointed Company Secretary on 12 January 2023.
Rob brings a wealth of experience and expertise to the Company
from his role as General Counsel and Company Secretary at Bestway
Wholesale (formerly Costcutter Supermarkets Group). He has over 15
years of UK and international experience across multiple sectors,
including retail, fast-moving consumer goods, manufacturing,
innovation and FinTech. His knowledge in legal, risk and compliance
has been gained through working with SMEs and quoted companies such
as SABMiller plc. He has been recognised for his work by being
listed in Legal 500's GC Powerlists in 2021 and 2022 and as a Team
of the Year finalist at The Lawyer Awards in 2021.
Clarissa Sowemimo-Coker, interim CEO said: "We are delighted to
welcome Rob to OCTP. His experience in the UK and internationally
is hugely beneficial to us, as is his expertise in M&A. He is
quickly becoming a valued member of our team."
Notice of Results & Analyst and Investor Presentations
The Company intends to announce results for the six-month period
ended 31 October 2022 on Monday 23 January 2023.
Analyst Briefing, 09.30, Monday 23 January 2023
A briefing for analysts will be held at 09.30 GMT on the day of
the results.
Analysts interested in attending should contact Walbrook PR by
emailing oxcantech@walbrookpr.com or by calling 020 7933 8780.
Investor Presentation, 16.30, Monday 23 January 2023
A live online presentation via the Investor Meet Company
platform will also be held at 16.30 GMT on Monday 23 January 2023,
which is open to all existing and potential shareholders.
Investors can sign up to Investor Meet Company for free and add
to meet Oxford Cannabinoid Technologies Holdings plc via:
https://www.investormeetcompany.com/oxford-cannabinoid-technologies-holdings-plc/register-investor
Investors who already follow OCTP on the Investor Meet Company
platform will automatically receive an invitation to the event.
The Directors of the Company accept responsibility for the
content of this announcement.
Enquiries:
Oxford Cannabinoid Technologies Holdings +44 (0)20 3034 2820
plc clarissa@oxcantech.com
Clarissa Sowemimo-Coker (Interim CEO)
Cairn Financial Advisers LLP
Emily Staples +44 (0)20 7213 0897
Jo Turner +44 (0) 20 7213 0885
Axis Capital Markets Limited
Kamran Hussain +44 (0)20 3026 0320
Richard Hutchison
finnCap Ltd
Geoff Nash/Fergus Sullivan +44 (0) 20 7220 0500
Nigel Birks (ECM)
Walbrook PR Limited +44 (0)20 7933 8780
Paul Vann/Nick Rome +44 (0)7768 807631
oxcantech@walbrookpr.com
About Oxford Cannabinoid Technologies Holdings Plc:
Oxford Cannabinoid Technologies Holdings plc ("OCTP") is the
holding company of a pharmaceutical Group developing prescription
cannabinoid medicines targeting the U$ multi-billion global pain
market.
OCTP currently has a portfolio of four drug development
programmes. Its lead compound, OCT461201, will initially target
neuropathic and visceral pain (including irritable bowel syndrome
("IBS") and chemotherapy induced peripheral neuropathy ("CIPN")),
with Phase 1 clinical trials, aimed at demonstrating safety and
tolerability, due to commence in the near term. Trial results are
expected in Q2 2023. The global market for CIPN alone was valued at
US$1.61bn in 2020 and is forecast to reach US$2.37bn by the year
2027.
OCTP's drug development pipeline, comprises both natural and
synthetic compounds, and includes compounds targeting trigeminal
neuralgia, a severe type of face pain, and cannabinoid derivatives
targeting pain and potentially other therapeutic areas. Having
established an exclusive license agreement with Canopy Growth
Corporation for their entire pharmaceutical cannabinoid derivative
library, OCTP now has a portfolio of over 400 derivatives and
intellectual property rights including 14 patent families and
associated research data.
OCTP has a clearly defined path to commercialisation, revenues
and growth. The Group is developing drug candidates through
clinical trials to gain regulatory approval (FDA/MHRA/EMA) that
will enable medical professionals to prescribe them with
confidence. OCTP's portfolio aims to balance risk, value and time
to market, whilst ensuring market exclusivity around all its key
activities.
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed
to be, forward looking statements. Forward looking statements are
identi ed by their use of terms and phrases such as "believe",
"could", "should" "envisage", "estimate", "intend", "may", "plan",
"potentially", "expect", "will" or the negative of those,
variations or comparable expressions, including references to
assumptions. These forward-looking statements are not based on
historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of
operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof),
competitive advantages, business prospects and opportunities. Such
forward looking statements re ect the Directors' current beliefs
and assumptions and are based on information currently available to
the Directors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORGPUPPGUPWGUW
(END) Dow Jones Newswires
January 16, 2023 02:00 ET (07:00 GMT)
Oxford Cannabinoid Techn... (LSE:OCTP)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Cannabinoid Techn... (LSE:OCTP)
Historical Stock Chart
From May 2023 to May 2024